Funds continue to pour in, and four "double-up funds" for the birth of innovative drugs within the year.

In the second half of the year, with the stock market index hitting a recent high, the strong pharmaceutical sector continues to shine. Both mainland and Hong Kong stocks in the innovative drug sector are on the rise, and related fund net values are also trending upwards, with four funds already doubling their net values this year. However, recent second quarter reports from funds have shown signs of loosening funds: although some innovative drug theme products have performed well, their market shares have decreased significantly in the second quarter. Some fund managers have stated that they have been cashing in on profits from high-congestion stocks. Additionally, with overall valuations rising, several fund managers believe that it is necessary to continue meticulously selecting stocks within the sector based on financial and research and development perspectives.